What happened?
The 2026 Annual Report to the Nation analysed US cancer incidence (2003–2022) and mortality (2004–2023). Cancer death rates fell each year from 2019 to 2023. Lung cancer deaths fell substantially from 2004–2023 (52% in males, 37% in females). New cancer cases rose modestly (~0.2%/yr, 2018–2022), driven by breast and prostate cancers.
Why does it matter?
Fewer lung cancer deaths are attributed to large declines in cigarette smoking and secondhand smoke exposure, increases in early-stage detection and greater survival from treatment advances. Lung screening uptake among eligible adults rose from 4.5% in 2015 to 18.7% in 2024, per the report.
How to interpret the evidence
Findings come from US cancer registries and national death records and describe population-level trends, not effects of a single trial or intervention. Applicability to EU/Malta is indirect: similar prevention, screening and treatment measures could affect local trends, but local data and access determine relevance.
What remains uncertain?
This observational report does not recommend individual treatments or state that new therapies are approved or available in Malta. Small changes in national incidence do not necessarily change individual risk. Trends may reflect detection, coding or surveillance differences.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.